tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia D007938 74 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Hematoma D006406 5 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Glomerulonephritis D005921 35 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Hypoglycemia D007003 13 associated lipids
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Pancytopenia D010198 6 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Brain Edema D001929 20 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Gingivitis D005891 3 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Brain Ischemia D002545 89 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Ischemia D007511 18 associated lipids
Glycosuria D006029 10 associated lipids
Seizures D012640 87 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schnitzler M Diabetes mellitus after kidney transplantation in the United States. 2003 Am. J. Transplant. pmid:14510709
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Lemahieu W et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. 2005 Am. J. Transplant. pmid:15888045
Axelrod D et al. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. 2005 Am. J. Transplant. pmid:15888050
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Djamali A et al. Nox2 is a mediator of chronic CsA nephrotoxicity. 2012 Am. J. Transplant. pmid:22568654
Cavadas PC et al. Bilateral trans-humeral arm transplantation: result at 2 years. 2011 Am. J. Transplant. pmid:21521475
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
English RF et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. 2002 Am. J. Transplant. pmid:12243498
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Al-Massarani G et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. 2008 Am. J. Transplant. pmid:18925903
Schold JD The burden of proof in the design of early phase clinical trials. 2013 Am. J. Transplant. pmid:23802723
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Willicombe M et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. 2011 Am. J. Transplant. pmid:21299828
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Meier-Kriesche HU et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. 2005 Am. J. Transplant. pmid:16095509
Senior PA et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. 2005 Am. J. Transplant. pmid:16095517
Rodríguez-Perálvarez M et al. Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. 2013 Am. J. Transplant. pmid:23621166
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Vanhove T et al. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. 2017 Am. J. Transplant. pmid:28224698
Awadalla Y et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. 2004 Am. J. Transplant. pmid:15367226
Borrows R et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. 2006 Am. J. Transplant. pmid:16433766
Shihab F et al. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. 2017 Am. J. Transplant. pmid:28141897
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
O'Connell PJ et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. 2013 Am. J. Transplant. pmid:23668890
Russ GR et al. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. 2013 Am. J. Transplant. pmid:23668931
Rodríguez-Perálvarez M et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. 2012 Am. J. Transplant. pmid:22703529
Budde K How to use mTOR inhibitors? The search goes on. 2011 Am. J. Transplant. pmid:21668636
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Chen G et al. Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. 2007 Am. J. Transplant. pmid:17227555
Senior PA et al. Changes in renal function after clinical islet transplantation: four-year observational study. 2007 Am. J. Transplant. pmid:17227560
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Asberg A et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. 2010 Am. J. Transplant. pmid:20486914
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Hautz T et al. Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. 2010 Am. J. Transplant. pmid:20353468
Zheng H et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. 2003 Am. J. Transplant. pmid:12694072
Ahsan N et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. 2002 Am. J. Transplant. pmid:12118902
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Triñanes J et al. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. 2017 Am. J. Transplant. pmid:28432716
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Pallet N et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. 2016 Am. J. Transplant. pmid:26990694
Rogers J et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. 2003 Am. J. Transplant. pmid:14510702